Clear Brain
Clear Brain, licence 80069839: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- New Nordic Inc.
- NPN or DIN-HM
- 80069839
- Status
- Inactive licence
- Licence date
- 1 June 2016
- Revision date
- 27 September 2016
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 2.116 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitamine B12 Source : Cyanocobalamine | 1.35 mcg | 2.7 µg |
| Folate Source : Acide folique | 100.0 mcg | Not calculated |
| Acide pantothénique Source : D-Pantothénate de calcium | 3.5 mg | 7,000 µg |
| Juglans regia Source : Graine(s) | 25.0 mg | Not calculated |
| Camellia sinensis Source : Camellia sinensis - feuille Extraction ratio : 30:1 Dry plant equivalent : 2250 mg | 75.0 mg | Not calculated |
| Punica granatum Source : Punica granatum, Fruit | 75.0 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Extraction ratio : 50:1 Dry plant equivalent : 3000 mg Potency : 24.0 % Flavonoid glycosides | 60.0 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Potency : 6.0 % Terpene lactones | Not specified | Not calculated |
| Pinus pinaster Source : Écorce (tige) | 40.0 mg | Not calculated |
| Piper nigrum Source : Piper nigrum - fruit | 3.0 mg | Not calculated |
| Thiamine | 0.658 mg | 1,316 µg |
| Riboflavine Source : Riboflavine | 0.853 mg | 1,706 µg |
| Niacinamide Source : Niacinamide | 4.5 mg | Not calculated |
| Vitamine B6 Source : Chlorhydrate de pyridoxal | 1.058 mg | 2,116 µg |
Non-medicinal ingredients
cellulose, Glycérine, Stéarate de magnésium, Silice, Hypromellose, Croscarmellose sodium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Comprimé | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to support peripheral circulation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80069839
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.